Engineering and Production of the Light-Driven Proton Pump Bacteriorhodopsin in 2D Crystals for Basic Research and Applied Technologies by Stauffer, Mirko et al.
Protocol
Engineering and Production of the Light-Driven
Proton Pump Bacteriorhodopsin in 2D Crystals for
Basic Research and Applied Technologies
Mirko Stauffer 1 , Stephan Hirschi 1 , Zöhre Ucurum 1, Daniel Harder 1 ,
Ramona Schlesinger 2,* and Dimitrios Fotiadis 1,*
1 Institute of Biochemistry and Molecular Medicine, and Swiss National Centre of Competence in
Research (NCCR) TransCure, University of Bern, 3012 Bern, Switzerland;
mirko.stauffer@ibmm.unibe.ch (M.S.); stephan.hirschi@ibmm.unibe.ch (S.H.);
zoehre.ucurum@ibmm.unibe.ch (Z.U.); daniel.harder@ibmm.unibe.ch (D.H.)
2 Department of Physics, Genetic Biophysics, Freie Universität Berlin, 14195 Berlin, Germany
* Correspondence: r.schlesinger@fu-berlin.de (R.S.); dimitrios.fotiadis@ibmm.unibe.ch (D.F.)
Received: 6 July 2020; Accepted: 19 July 2020; Published: 22 July 2020


Abstract: The light-driven proton pump bacteriorhodopsin (BR) from the extreme halophilic archaeon
Halobacterium salinarum is a retinal-binding protein, which forms highly ordered and thermally stable
2D crystals in native membranes (termed purple membranes). BR and purple membranes (PMs)
have been and are still being intensively studied by numerous researchers from different scientific
disciplines. Furthermore, PMs are being successfully used in new, emerging technologies such
as bioelectronics and bionanotechnology. Most published studies used the wild-type form of BR,
because of the intrinsic difficulty to produce genetically modified versions in purple membranes
homologously. However, modification and engineering is crucial for studies in basic research and,
in particular, to tailor BR for specific applications in applied sciences. We present an extensive
and detailed protocol ranging from the genetic modification and cultivation of H. salinarum to the
isolation, and biochemical, biophysical and functional characterization of BR and purple membranes.
Pitfalls and problems of the homologous expression of BR versions in H. salinarum are discussed and
possible solutions presented. The protocol is intended to facilitate the access to genetically modified
BR versions for researchers of different scientific disciplines, thus increasing the application of this
versatile biomaterial.
Keywords: bacteriorhodopsin; bioelectronics; biomaterial; bionanotechnology; Halobacterium salinarum;
light-driven proton pump; protein engineering; purple membranes
1. Introduction
Since its discovery in 1971 [1], the light-driven proton pump bacteriorhodopsin (BR) from the
extreme halophilic archaeon Halobacterium salinarum (previously known as Halobacterium halobium) has
become an intensively studied model membrane protein for proton translocation across biological
membranes [2–5], photochemical events in proteins [6–9], photophosphorylation [10–12] and structural
studies [13–16]. The use of BR to study proton transport across membranes in different time scales
using time-resolved serial femtosecond crystallography at X-ray free electron lasers [17–20] and
as an alignment tool for NMR studies [21] highlights its significant contribution to emerging
technologies. BR natively occurs in patches in the membrane of H. salinarum, called purple
membranes (PMs). These patches contain BR and lipids in a hexagonal crystal lattice, with BR
forming trimers. This quaternary structure and higher order is responsible for the high thermal stability
of PMs [22,23]. Interesting chemical and physical properties, i.e., photochromism, photoelectrism and
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thermal stability make BR/PMs one of the most promising biomaterials for versatile technical and
scientific applications [24].
Upon illumination with light at 568 nm, the covalently bound retinal chromophore of BR
undergoes isomerization by absorbing a photon. This induces a photocycle, involving a series of
conformational changes and protonation states through different, consecutive states. These spectrally
distinguishable intermediates are called K, L, M and O, the last of which thermally decays back to
the resting state (bR) [8]. However, if the O intermediate absorbs a second photon (λmax = 640 nm),
an alternative intermediate, the thermally stable Q-state, can form enabling long-term storage of
information. This feature is exploited in the application of BR in holographic associative processors [25]
and volumetric optical memories [26,27]. During a complete photocycle, a proton is transported
from the intra- to the extracellular side of the protein, establishing an electric current (photocurrent).
This photoelectric effect is applied in photovoltaic devices [28], optical switches [29], optical logic
gates [30], light sensors [31], single electron [31]- and field effect transistors [32], chemical sensors [33,34],
optical microcavities [35] and may even lead to protein-based retinal implants [36].
The wild-type form of BR or purple membranes is not optimal for numerous applications;
thus, mutated forms were engineered to meet specific requirements. Furthermore, variants were
needed to conduct studies on mechanistic and structural aspects of BR. For example, in BR-D96N,
the duration of the photocycle increases from ~10 ms to ~10 s, which allowed for studying the
conformational changes by high-speed atomic force microscopy [37]. The introduction of common
protein tags such as the His-tag [38,39] or the creation of fusion proteins such as BR-GFP [40] enable
the use of specific biophysical and bionanotechnological techniques. By the modulation of the
energetic state of certain photocycle species, BR can be tailored to specific applications. The previously
mentioned BR-D96N shows a prolonged lifetime of the M state, leading to an enhanced light sensitivity,
which finds application in optical and holographic recordings [28]. In contrast, BR-D85N [41] and
BR-V49A/I119T/T121S/A126T [24] show the prolonged lifetime of the O-state, leading to a more efficient
formation of the Q-state, which is needed for long-term information storage. BR can also be optimized
for photovoltaic applications by enhancing the dipole moment of the purple membranes [24]. If BR is
used in photodetector or photovoltaic devices, a high photocurrent is required for efficient operation.
A possibility to enhance the photocurrent is increasing the molecular surface density of BR on the used
electrode. This was accomplished by engineering the BR-M163C version, which is able to bind to the
gold electrode surface via the introduced cysteine residue [42].
The genetic modification of H. salinarum was first established using a polyethyleneglycol
(PEG)-mediated transformation method [43,44]. The introduction of resistance genes for the antibiotics
mevinolin [45–47] and novobiocin [48,49] into haloarchaeal plasmids for the selection of transformants
and the development of shuttle-vectors [50–52], which enabled mutagenesis and vector amplification
in Escherichia coli, further simplified the transformation of H. salinarum. The transformation of purple
membrane-deficient strains (e.g., H. salinarum L33 [53,54]), in which the bacterioopsin (bop) gene is
disrupted by transposable elements [54], with plasmids containing wild-type or mutant versions of
the bop gene, allowed for the homologous expression of purple membranes containing wild-type or
mutant versions of BR [50,51]. In parallel, methods for heterologous expression of BR in E. coli [55–58]
were developed. However, this approach requires supplementation of retinal to culture media,
host-specific signal sequences for membrane targeting, which have to be proteolytically removed
later, as well as the purification of BR using detergents followed by reconstitution into lipids to yield
functional BR. Furthermore, it was demonstrated that functional BR can be expressed in the yeast
Schizosaccharomyces pombe, without the need for added signal sequences [59,60]. Importantly, it is
not possible to produce BR as purple membranes using these expression systems [55]. It is therefore
not recommended to use heterologous expression for applications, which require BR organized in
a 2D lattice as found only in purple membranes from halobacteria. Methods for the cultivation of
H. salinarum [61,62] and the isolation of purple membranes [63] were established early in BR research
and were adapted in many scientific publications, including this protocol.
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Here, we present a detailed and straightforward description for the production of specifically
engineered PMs, from the genetic modification and cultivation of H. salinarum to the isolation of pure
PMs. Furthermore, we show functional and biophysical techniques for the analysis of those PMs.
These methods allow for the production of a wide range of PMs with different forms of mutations,
including the addition of different detection and purification tags, the introduction of functional point
mutations and the production of fusion proteins. Even chimeras of BR and other proteins were shown
to be functionally active, while maintaining the structural integrity of the two-dimensional crystalline
PM lattice [64]. Intrinsic problems of the H. salinarum expression system are discussed and possible
solutions presented.
2. Experimental Design
The time needed to perform the experiments in this protocol can strongly vary, depending on the
number of iteration cycles needed to achieve a satisfactory clone.
3.1 Site-directed mutagenesis of bop in pUC18 (0.5 Day)
3.2 Insertion of bop-C-His10 into pHS blue (0.5 Day)
3.3 Amplification of pHS blue-bop-C-His10 in E. coli DH5α (1 Week)
3.4 Preparation of H. salinarum L33 cells for transformation (2–3 Days)
3.5 Preparation of plasmid for transformation (10 Min)
3.6 Transformation of H. salinarum L33 (2 H)
3.7 Outgrowth of transformed cells (2 Days)
3.8 Plating and colony formation (1–2 Weeks)
3.9 Colony picking and cultivation (1 Week)
3.10 Glycerol stock preparation (30 Min)
3.11 Clone screening by small-volume purple membrane preparation (0.5 Day)
3.12 Evaluation of BR expression by Coomassie Brilliant blue-stained SDS-PAGE and Western blot
analysis (0.5 Day)
3.13 Iterative clone-picking to optimize expression of His10-tagged bacteriorhodopsin (2–3 Weeks
per iteration)
3.14 Large-volume cultivation of a selected transformed H. salinarum L33 clone (2 Weeks)
3.15 Purple membrane preparation (1.5 Days)
3.16 Detergent-mediated reconstitution of BR into preformed liposomes (2 Days)
3.17 Functional characterization of BR proteoliposomes by photoactivity assay (1 Day)
3.18 Structural characterization of purple membranes by negative stain transmission electron microscopy
(1 Day)
2.1. Materials
• Phusion High-Fidelity PCR Kit (Thermo Fisher, Reinach, Switzerland; cat. no. F553L)
• 5′-pUC-BamHI-BR (forward primer): AAA AGG ATC CGA CGT GAA GAT GGG GC (Microsynth
AG, Balgach, Switzerland; custom synthesis)
• 3′-BR-C-His10-HindIII (reverse primer): AAA AAA GCT TGA TTC AGT GGT GAT GAT GGT
GAT GAT GGT GGT GAT GTC CGT CGC TGG TCG CGG CCG CGC (Microsynth AG, Balgach,
Switzerland; custom synthesis)
• Primer for D96N mutation in BR-C-His10: CCG CTG TTG TTG TTA AAC CTC GCG TTG CTC
GTT G (Microsynth AG, Balgach, Switzerland; custom synthesis)
• The plasmid pUC18-bop, i.e., the promotor and the gene of BR (bop) inserted into the commercially
available pUC18 vector (New England BioLabs, Allschwil, Switzerland; cat. no. N3041)
• Gel extraction/PCR purification kit (NucleoSpin Gel and PCR Clean-up Kit, Macherey-Nagel,
Oensingen, Switzerland; cat. no. 740609)
• DNA Ligation Kit (Thermo Fisher, Reinach, Switzerland; cat. no. K1423)
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• E.Z.N.A. Plasmid Mini Kit I (VWR, Dietikon, Switzerland; cat. no. D6943-02)
• BamHI-HF (New England BioLabs, Allschwil, Switzerland; cat. no. R3136S)
• HindIII-HF (New England BioLabs, Allschwil, Switzerland; cat. no. R3104S)
• CutSmart buffer 10X (New England BioLabs, Allschwil, Switzerland; cat. no. B7204S)
• DH5α competent cells (Thermo Fisher, Reinach, Switzerland; cat. no. 18265017)
• plasmid pHS blue (shuttle vector: E. coli and H. salinarum) [39]. See Supplementary Information
for nucleotide sequence (Material S1) and vector map (Figure S1)
• Agarose (Sigma-Aldrich, Buchs, Switzerland; cat. no. A9539)
• Tris (AppliChem, Bioswisstec, Schaffhausen, Switzerland; cat. no. A1430)
• Acetic acid (Sigma-Aldrich, Buchs, Switzerland; cat. no. 695092)
• Ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich, Buchs, Switzerland; cat. no. EDS)
• Luria-Bertani (LB) broth (VWR, Dietikon, Switzerland; cat. no. J106)
• Kanamycin sulfate (AppliChem, Bioswisstec, Schaffhausen, Switzerland; cat. no. 1493)
• Bacto™ Agar (BD, Allschwil, Switzerland; cat. no. 214010)
• E.Z.N.A. Plasmid Midi Kit (VWR, Dietikon, Switzerland; cat. no. D6904-03)
• Sodium chloride Ph.Eur/USP (NaCl; Schweizer Salinen, Pratteln, Switzerland; www.salz.ch,
cat. no. 7731)
• Magnesium sulfate (MgSO4; Sigma-Aldrich, Buchs, Switzerland; cat. no. M2643)
• Trisodium citrate dihydrate (Merck, Zug, Switzerland; cat. no. 106448)
• Potassium chloride (KCl; Sigma-Aldrich, Buchs, Switzerland; cat. no. 60310)
• Bacteriological peptone (OXOID, Pratteln, Switzerland; cat. no. LP0037)
Methods Protoc. 2020, 3, x FOR PEER REVIEW 4 of 21 
 
• BamHI-HF (New England BioLabs, Allschwil, Switzerland; cat. no. R3136S) 
• HindIII-HF (New England BioLabs, Allschwil, Switzerland; cat. no. R3104S) 
• CutSmart buffer 10X (New England BioLabs, Allschwil, Switzerland; cat. no. B7204S) 
• DH5α competent cells (Thermo Fisher, Reinach, Switzerland; cat. no. 18265017) 
• plasmid HS blue (shuttle vector: E. coli and H. salinarum) [39]. See Supplementary Information 
for nucleotide sequence (Material S1) and vector map (Figure S1) 
• Agarose (Sigma-Aldrich, Buchs, Switzerland; cat. no. A9539) 
• Tris (AppliChem, Bioswisstec, Schaffhausen, Switzerland; cat. no. A1430) 
• Acetic acid (Sigma-Aldrich, Buchs, Switzerland; cat. no. 695092) 
• Ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich, Buchs, Switzerland; cat. no. EDS) 
• Luria-Bertani (LB) broth (VWR, Die ikon, Switzerla d; cat. no. J106) 
• Kanamycin sulfate (AppliChem, Bioswisstec, Schaffhausen, Switzerland; cat. no. 1493) 
• Bacto™ Agar (BD, Allschwil, Switzerland; cat. no. 214010) 
• E.Z.N.A. Plasmid Midi Kit (VWR, Dietikon, Switzerland; cat. no. D6904-03) 
• Sodium chloride Ph.Eur/USP (NaCl; Schweizer Salinen, Pratteln, Switzerland; www.salz.ch, cat. 
no. 7731) 
• Magnesium sulfate (MgSO4; Sigma-Aldrich, Buchs, Switzerland; cat. no. M2643) 
• Trisod  citrate ihydrate (Merck, Zug, Switzerland; ca . no. 106448) 
• Potassium chloride (KCl; Sigma-Aldrich, Buchs, Switzerland; cat. no. 60310) 
• Bacteriological peptone (OXOID, Pratteln, Switzerland; cat. no. LP0037) 
 CRITICAL Other peptone products might not work optimally. 
• Sodium hydroxide (NaOH; Sigma-Aldrich, Buchs, Switzerland; cat. no. S8045) 
• Milli-Q ultrapure water (from Millipore water system) 
• Deionized water from in-house system 
• H. salinarum strain S9 [65] 
• H. salinarum strain L33 [53,66] 
• Novobiocin sodium salt (Sigma-Aldrich, Buchs, Switzerland; cat. no. N1628) 
• Hydrochloric acid (HCl) fuming, ≥37% (Sigma-Aldrich, Buchs, Switzerland; cat. no. 30721) 
‘CAUTION’ Highly corrosive. Work in a fume hood and wear goggles and protective clothing. 
• Polyethylene glycol 600 (PEG600; Sigma-Aldrich, Buchs, Switzerland; cat. no. 87333) 
• Sucrose (Sigma-Aldrich, Buchs, Switzerland; cat. no. S7903) 
• Calcium chloride dihydrate (CaCl2; Merck, Zug, Switzerland; cat. no. 102382) 
• Deoxyribonuclease I from bovine pancreas (DNase; Sigma-Aldrich, Buchs, Switzerland; cat. no. 
DN25) 
• Sodium azide (NaN3; AppliChem, Bioswisstec, Schaffhausen, Switzerland; cat. no. A1430) 
‘CAUTION’ Highly toxic substance. Needs special handling and waste disposal. 
• Coomassie Brilliant blue R-250 (AppliChem, Bioswisstec, Schaffhausen, Switzerland; cat. no. 
A1092) 
• Immobilon-P polyvinylidene difluoride (PVDF) transfer membrane (Merck Millipore Ltd., Zug, 
Switzerland; cat. no. IPVH00010) 
• Albumin from bovine serum (BSA, Sigma-Aldrich, Buchs, Switzerland; cat. no. A3912) 
• Tween 20 (AppliChem, Bioswisstec, Schaffhausen, Switzerland; cat. no. A4974) 
• Anti-penta-His mouse primary antibody (Qiagen, Hombrechtikon, Switzerland; cat. no. 34660) 
• Goat anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibody (Bio-Rad, 
Cressier, Switzerland; cat. no. 172-1011) 
• Amersham ECL Western Blotting Detection Reagents (GE Healthcare, Opfikon, Switzerland; cat. 
no. RPN2209) 
• Super RX-N Fuji Medical X-ray film (Fujifilm, Dielsdorf, Switzerland; cat. no. 47,410 19284) 
• Glycerol (Sigma-Aldrich, Buchs, Switzerland; cat. no. 49770) 
• 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) dissolved in chloroform (Avanti Polar 
Lipids, Alabaster, AL, USA; cat. no. 850375) 
• Nitrogen (or any other inert) gas 
I I AL Other peptone products might n t work optimally.
• Sodium hydroxide (NaOH; Sigma-Aldrich, Buchs, Switzerland; cat. no. S8045)
• Milli-Q ultrapure water (from Millipore water system)
• Deionized water from in-house system
• . li ru strain S9 [65]
• H. salinarum strain L33 [53,66]
• Novobiocin sodium salt (Sigma-Aldrich, Buchs, Switzerland; cat. no. N1628)
• Hydrochloric acid (HCl) fuming, ≥37% (Sigma-Aldrich, Buchs, Switzerland; cat. no. 30721)
‘CAUTION’ Highly corrosive. Work in a fume hood and wear goggles and protective clothing.
• Polyethylene glycol 600 (PEG600; Sigma-Aldrich, Buchs, Switzerland; cat. no. 87333)
• Sucrose (Sigma-Aldrich, Buchs, Switzerland; cat. no. S7903)
• Calcium chloride dihydrate (CaCl2; Merck, Zug, Switzerland; cat. no. 102382)
• Deoxyribonuclease I from bovine pancreas (DNase; Sigma-Aldrich, Buchs, Switzerland;
cat. no. DN25)
• Sodium azide (NaN3; AppliChem, Bioswisstec, Schaffhausen, Switzerland; cat. no. A1430)
‘CAUTION’ Highly toxic substance. Needs special handling and waste disposal.
• Coomassie Brilliant blue R-25 (AppliChem, Bioswisstec, Schaffhausen, Switzerland; cat. no. A1092)
• Immobilon-P polyvinylidene difluoride (PVDF) transfer membrane (Merck Millipore Ltd., Zug,
Switzerland; cat. no. IPVH00010)
• Albumin from bovine serum (BSA, Sigma-Aldrich, Buchs, Switzerland; cat. no. A3912)
• Tween 20 (AppliChem, Bioswisstec, Schaffhausen, Switzerland; cat. no. A4974)
• nti-penta-His mouse primary antibody (Qiagen, Hombre htikon, Switzerland; cat. no. 34660)
• G at anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibody (Bio-Rad, Cressier,
Switzerland; cat. no. 172-1011)
• Amersham ECL Western Blotting Detection Reagents (GE Healthcare, Opfikon, Switzerland;
cat. no. RPN2209)
Methods Protoc. 2020, 3, 51 5 of 22
• Super RX-N Fuji Medical X-ray film (Fujifilm, Dielsdorf, Switzerland; cat. no. 47,410 19284)
• Glycerol (Sigma-Aldrich, Buchs, Switzerland; cat. no. 49770)
• 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) dissolved in chloroform (Avanti Polar Lipids,
Alabaster, AL, USA; cat. no. 850375)
• Nitrogen (or any other inert) gas
• n-octyl-β-D-glucopyranoside (OG, Glycon Biochemicals, Luckenwalde, Germany; cat. no. D97001)
• Potassium phosphate monobasic (KH2PO4, Sigma-Aldrich, Buchs, Switzerland; cat. no. P5655)
• Potassium phosphate dibasic (K2HPO4, Sigma-Aldrich, Buchs, Switzerland; cat. no. P3786)
• Uranyl formate (Thomas Scientific, cat. no. C993L42). ‘CAUTION’ Highly toxic substance.
Needs special handling and waste disposal according to radioactivity regulations.
2.2. Equipment
• PCR cycler: we use a SensoQuest Labcycler
• Agarose gel electrophoresis apparatus
• pH meter: we use a Seven Compact pH meter (Mettler Toledo, cat. no. 30019028)
• Filters for media sterilization: we use Jet Biofil Filter Upper Cups 0.22 µm (Axonlab,
cat. no. FPE-214-000)
• Incubator for liquid cultures: we use an Infors HT Multitron Standard incubator
• Spectrophotometer for liquid cultures: we use a Pharmacia Biotech Ultraspec 3000
UV-visible spectrophotometer
• Light microscope: we use a Leitz Laborlux 11 light microscope
• Incubator for agar plates: we use a Memmert TNB400 incubator
• Centrifuge for 15 mL and 50 mL conical vials: we use a Beckman Coulter Allegra X-15R centrifuge
• Centrifuge for 1.5 mL and 2 mL test tubes: we use an Eppendorf Centrifuge 5424R
• Ultracentrifuge for 1 mL tubes: we use a Beckman Coulter OptimaTM MAX-XP ultracentrifuge
• For membrane homogenization we use a glass homogenizer size 19 (1 mL) from Kontes Glass Co
• For chromophore-based protein quantification we use a NanoDrop 1000 spectrophotometer
(Thermo Fisher, Reinach, Switzerland)
• SDS-PAGE apparatus: we use a Bio-Rad Mini-PROTEAN Tetra System
• Blotting apparatus for Western blot: we use a Bio-Rad TransBlot SD Semi-Dry Transfer Cell
• Centrifuge for 1 L bottles: we use a Herolab HiCen XL centrifuge
• Ultracentrifuge for 94 mL tubes: we use a Beckman Coulter OptimaTM L-90K ultracentrifuge
• 10 mL round bottom flasks with glass stoppers and suitable holder
• Desiccator equipped with a vacuum pump: we use a Nalgene plastic desiccator (Thermo Fisher,
Reinach, Switzerland)
• Thermoshaker for 1–2 mL sample tubes: we use an Eppendorf ThermoMixer C
• Extruder with heating block and two gas tight syringes: we use an Avanti Mini-Extruder (Avanti cat.
no. 610000) and two 1 mL gas tight syringes (Avanti, cat. no. 610017)
• Membranes for extruder: we use polycarbonate membranes with pore size 0.2 µm (Avanti,
cat. no. 610006)
• Filter supports for extruder: we use 10 mm filter supports (Avanti, cat. no. 610014)
• Dialysis tubing: we use 10 mm Membra-Cel dialysis tubing with molecular weight cut-off 14 kDa
(Membra-Cel, Roth, cat no. 1780.1)
• Plastic clips: we use Spectrum Dialysis Tubing Closures (Spectra/Por, cat. no. 888-11614)
• 2 L beaker or Erlenmeyer flask
• Unautoclaved 2 mL sample tubes
• Magnetic stirrer and magnetic stir bar
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• Temperature regulated water bath with connective tubing and a glass cooling cell: we use a Julabo
F10 ultrapure water bath (Gemini, cat. no. 01819) and a SONOPULS KG 3 (Faust, cat. no. 9.650
235) glass cooling cell with water jacket
• Micro pH electrode with integrated temperature sensor: we use an InLab Micro Pro-ISM electrode
(Mettler Toledo, cat. no. 51344163)
• Computer with LabX direct pH 2.3 software (Mettler Toledo)
• Warm white LED lamp: we use a JANSÖ LED lamp (IKEA, cat. no. 903.860.12)
• Laboratory film: we use Parafilm M sealing film
• Syringe and filter: we use disposable 10 mL syringes ONCE/CODAN (HUBERLAB, cat. no.
3.7410.06) and single use hydrophilic 0.2 µm Sartorius Minisart syringe filters (fisher scientific,
cat. no. 10730792)
• Carbon-coated copper electron microscopy grids: we use 400 mesh copper grids with a thin
carbon film (Gridtech, cat. no. Cu-400CN)
• Microscope slide
• Glow discharge system including a high voltage power supply and a vacuum chamber: we use a
custom build but any commercially available system works
• Precision forceps: we use 0.1 × 0.06 mm Dumont Dumoxel Tweezers #5 (World Precision
Instruments, cat. no. 14098)
• Blotting paper for microscope slides: we use Macherey-Nagel MN 224 blotting paper for
microscope slides
• Electron microscopy grid storage box: we use a grid storage box for 100 grids from Electron
Microscopy Sciences
• Transmission electron microscope: we use a FEI Tecnai Spirit transmission electron microscope
(Thermo Fisher, Reinach, Switzerland) equipped with an FEI Eagle CCD camera
3. Procedure
3.1. Site-Directed Mutagenesis of Bop in pUC18 (0.5 Day)
• Introduce a C-terminal His10-tag into the bop gene, which encodes wild-type BR (BR-wt), by PCR
with pUC18-bop as a template, 5′-pUC-BamHI-BR as a forward primer and 3′-BR-C-His10-HindIII
as a reverse primer (see Section 2.1). You can use a PCR kit of your choice, we use the Phusion
High-Fidelity PCR kit. Prepare the following PCR master mix (Table 1) on ice or follow the
manufacturer’s instructions for your preferred kit:
Table 1. PCR reaction mixture for site-directed mutagenesis of the bop gene.
Component Amount (µL) Final Concentration
pUC18-bop plasmid template
1 2 ng/µL(100 ng/µL)
5′-pUC-BamHI-BR forward primer
1 2 pM(100 pM)
3′-BR-C-His10-HindIII reverse primer 1 2 pM(100 pM)
dNTP’s (10 mM for each dNTP) 1 200 µM
Phusion CG buffer (5X) 10 1X
DMSO (100%) 1.5 3%
Phusion DNA Polymerase (2 U/µL) 0.5 0.02 U/µL
Nuclease-free water 34
Total 50
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• Run the PCR reaction using the following program (Table 2):
Table 2. PCR program for site-directed mutagenesis of the bop gene.
Cycles Denaturation (94 ◦C) Annealing (63 ◦C) Elongation (72 ◦C)
1 2 min
32 45 s 45 s 1 min
1 10 min
• Purify your PCR product (bop-C-His10) using a PCR purification kit (see Section 2.1) and follow
the manufacturer’s instructions. We use an elution volume of 32 µL.
3.2. Insertion of Bop-C-His10 into pHS Blue (0.5 Day)
• Digest the purified PCR product with BamHI-HF and HindIII-HF. Prepare the following reaction
mixture (Table 3) and incubate for 1.5 h at 37 ◦C.
Table 3. Reaction mixture for the digestion of the PCR product.
Component Amount (µL) Final Concentration
Purified PCR product (350 ng/µL) 20 140 ng/µL
CutSmart buffer (10X) 5 1X
HindIII-HF (20 U/µL) 1 0.4 U/µL
BamHI-HF (20 U/µL) 1 0.4 U/µL
Nuclease-free water 23
Total 50
• In parallel, digest the pHS blue plasmid with BamHI-HF and HindIII-HF as well. Prepare the
following reaction mixture (Table 4) and incubate for 1.5 h at 37 ◦C.
Table 4. Reaction mixture for the digestion of the pHS blue plasmid.
Component Amount (µL) Final Concentration
pHS blue plasmid (2 µg/µL) 7 280 ng/µL
CutSmart buffer (10X) 5 1X
HindIII-HF (20 U/µL) 3 1.2 U/µL
BamHI-HF (20 U/µL) 3 1.2 U/µL
Nuclease-free water 32
Total 50
• Load the digested insert and the digested pHS blue plasmid on a 1% (w/v) agarose gel prepared
with TAE buffer and let it run.
• Cut out the resulting bands for the insert and the plasmid and purify them using a gel extraction
kit (see Section 2.1). Elute with a volume of 20 µL.
• Ligate the plasmid and the insert using a DNA ligation kit of your choice (see Section 2.1).
Prepare the following ligation reaction mixture (Table 5) and incubate it for 45 min at RT.
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Table 5. Reaction mixture for the ligation of pHS blue and the insert.
Component Amount (µL) Final Concentration
Digested pHS blue plasmid (130 ng/µL) 1 6.5 ng/µL
Digested insert (32 ng/µL) 14 22.5 ng/µL
Rapid ligation buffer (5X) 4 1X
T4 DNA ligase (5 U/µL) 1 0.25 U/µL
Total 20
3.3. Amplification of pHS Blue-Bop-C-His10 in E. coli DH5α (1 Week)
• Let 50 µL of E. coli DH5α competent cells thaw on ice.
• Add 5 µL of the ligation product (pHS blue plasmid with bop-C-His10 insert) to the competent
cells. Incubate on ice for 20 min.
• Incubate for 60 s at 42 ◦C.
• Incubate for 2 min on ice.
• Add 900 µL of LB and incubate at 700 rpm for 30 min at 37 ◦C in an Eppendorf tube shaker.
• Centrifuge at 14,000 rpm for 2 min at RT.
• Remove 880 µL of the supernatant.
• Resuspend the pellet in the remaining supernatant.
• Spread out the transformed cells on an LB-agar plate supplemented with 25 µg/mL kanamycin.
Incubate overnight at 37 ◦C.
• Pick 4 colonies from the LB-agar plate and, with each, inoculate 10 mL of LB medium supplemented
with 25 µg/mL kanamycin. Incubate at 180 rpm overnight at 37 ◦C.
• Use 5 mL of the overnight cultures to prepare glycerol stocks for each colony at a final concentration
of 20% glycerol.
• Isolate the pHS blue-bop-C-His10 plasmid from the remaining 5 mL of the overnight cultures of
each colony using a plasmid DNA isolation kit of your choice. We use an E.Z.N.A. Plasmid DNA
Mini Kit I with an elution volume of 60 µL.
• Measure the concentration of the isolated pHS blue plasmid by UV-Vis spectroscopy at 260 nm.
The OD260/OD280 ratio should be between 1.8 and 2.0, indicating pure DNA.
• Digest the isolated plasmids with BamHI-HF and HindIII-HF. Prepare the following reaction
mixture (Table 6) and incubate for 1.5 h at 37 ◦C.
Table 6. Reaction mixture for the digestion of the amplified plasmid.
Component Amount (µL) Final Concentration
Isolated pHS blue-bop-C-His10 (125 ng/µL) 8 100 ng/µL
CutSmart buffer (10X) 1 1X
HindIII-HF (20 U/µL) 0.5 1 U/µL
BamHI-HF (20 U/µL) 0.5 1 U/µL
Total 10
• Load the digested plasmid on a 0.8% (w/v) agarose gel prepared with TAE buffer and run the gel.
• The gel should show two bands, one for the vector (~10.7 kb) and one for the insert (~1.2 kb).
If that is the case, let the DNA of bacteriorhodopsin in the pHS blue-bop-C-His10 construct be
sequenced by a service company and check for your desired modification/mutation, and possible
random mutations. If the sequence of a clone is correct, inoculate 50 mL LB supplemented with
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25 µg/mL kanamycin with 5 µL glycerol stock of the corresponding clone and incubate at 180 rpm
overnight at 37 ◦C.
• Isolate the pHS blue-bop-C-His10 plasmid from the overnight culture using a plasmid DNA
isolation kit of your choice. We use an E.Z.N.A. Plasmid DNA Midi Kit I with an elution volume
of 500 µL. Measure the DNA concentration as described above.
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3.4. Preparation of H. Salinarum L33 Cells for Transformation (2–3 Days) 
• Inoculate 10 mL L37 medium in a 50 mL conical tube with 10 µL H. salinarum L33 from a glycerol 
stock. This suffices for four transformations. 
• Incubate the culture at 170 rpm and 40 °C until the OD600 is between 0.6 and 0.8, typically reached 
after 2–3 days. 
3.5. Preparation of Plasmid for Transformation (10 Min) 
• Place a volume containing 3 µg of the pHS blue-bop-C-His10 plasmid at the bottom of a 15 mL 
conical vial, add 5 M NaCl to the drop to reach a final concentration of 2 M (e.g., 3 µL plasmid 
(1 µg/µL) + 2 µL 5 M NaCl) and mix the resulting drop with a pipette. Close the tube to avoid 
evaporation and store at room temperature until it is used for transformation. 
3.6. Transformation of H. salinarum L33 (2 H) 
S bl e-bop- - is10 las i s ca be store at 20 ◦ for years.
3.4. reparation of . salinarum L3 Cells for Transformation (2–3 Days)
• Inoculate 10 mL L37 medium in a 50 L conical tube ith 10 L . salinaru L33 fro a lycerol
stock. This suffices for four transformations.
• Incubate the culture at 170 rpm and 40 ◦C until the OD600 . . , i ll reached
after 2–3 days.
3.5. reparation of Plas id for Transformation (10 Min)
• Place a volume containing 3 µg of the pHS blue-bop-C-His10 l s i t t e tt f a 15 L
conical vial, add 5 NaCl to the drop to reach a final concentration of 2 (e.g., 3 µL plas id
(1 µg/µL) + 2 µL 5 M NaCl) and mix the resulting drop with a pipette. Close the tube to avoid
evaporation and store at ro m temperature until it is used for transformation.
3.6. Transformation of H. salinarum L33 (2 H)
• Pellet the H. salinarum culture at 4000× g for 15 min at room temperature, discard the supernatant,
resuspend the pellet in 1 mL of SPH and take a 50 µL sample for spheroplast formation control.
• Add 50 µL of EDTA solution to the resuspended cells, gently mix by shaking the tube by hand
and take another 50 µL sample.
• Check the formation of spheroplasts by comparing the 50 µL samples before and after EDTA
addition in a light microscope. Normal H. salinarum L33 cells are motile rods (Figure 1a), while
spheroplasts are round and only move by Brownian motion (Figure 1b).
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• If all cells turned from rods to spheroplasts, add 200 µL of the resuspended cells to the 15 mL
conical vial containing the plasmid and incubate for 20 min at room temperature.
• Carefully add an equal volume of PEG solution to the spheroplast-DNA-mix (200 µL spheroplasts
+ volume of diluted DNA, e.g., 5 µL) and incubate for 20 min at room temperature.
• Fill up the conical vial to 10 mL with spheroplast dilution solution and incubate for 30 min at
40 ◦C.
3.7. Outgrowth of Transformed Cells (2 Days)
• Pellet the cells at 4000× g for 10 min at room temperature and resuspend in 1 mL regeneration
medium. Place the tube horizontally in the incubator instead of standing in a rack and incubate at
180 rpm and 37 ◦C for 2 days.
3.8. Plating and Colony Formation (1–2 Weeks)
• Dilute the transformed cells and spread out 50 µL on L37-agar plates supplemented with 0.3 µg/mL
novobiocin. As transformation efficiency varies strongly, try different dilutions (e.g., 1:100 and
1:1000). Seal the plates in plastic bags or with plastic tape to avoid evaporation during incubation
(see Section 5.2). Incubate at 37 ◦C for 1–2 weeks.
3.9. Colony Picking and Cultivation (1 Week)
• Pick 10–20 colonies from the L37-agar plates (Figure 2) and with each, inoculate 20 mL of L37
supplemented with 0.3 µg/mL novobiocin in a 50 mL conical vial. Incubate at 170 rpm and 40 ◦C
for 1 week.Methods Protoc. 2020, 3, x FOR PEER REVIEW 10 of 21 
 
 CRITICAL STEP Try to pick colonies of different sizes and colour intensities. Colonies with 
a strong red colour may express considerable amounts of BR-wt. In our specific case, the colours 
did not vary significantly and the size of the clones did not correlate with the ratio of BR-C-His10 
to BR-wt. 
 
Figure 2. L37-agar plate of H. salinarum L33 transformed with BR-C-His10. A total of 50 µL of H. 
salinarum L33 cells transformed with BR-C-His10 was plated out after 2 days of outgrowth in a dilution 
of 1:100 and incubated at 37 °C for two weeks. Shown is an excerpt of the plate 4 × 4 cm in size. 
3.10. Glycerol Stock Preparation (30 Min) 
• Centrifuge 8 mL of each culture at 4000× g for 15 min at room temperature and resuspend in 3.2 
mL L37. Add 800 µL of 50% (w/v) glycerol solution to reach a final concentration of 10%. Freeze 
with liquid nitrogen and store at −80 °C. 
3.11. Clone Screening by Small-Volume Purple Membrane Preparation (0.5 Day) 
• Centrifuge 10 mL of each culture at 5000× g for 15 min at 4 °C, resuspend in 1.6 mL basal salt 
and transfer the sample to a 2 mL Eppendorf tube. Centrifuge at 8000× g for 5 min at 4 °C and 
discard the supernatant. 
• Add 700 µL of 10 mM MgSO4 supplemented with 30 µg DNAse (=12 µL of a 2.5 mg/mL solution). 
Lyse the cells by resuspending with a pipette until the solution is homogeneous. 
 CRITICAL STEP Remaining DNA leads to a viscous, inhomogeneous purple membrane 
sample and reduces the yield. 
• Remove the cell debris by centrifuging the samples at 4300× g for 1 min at 4 °C, followed by two 
centrifugations at 7000× g for 1 min at 4 °C. Transfer the supernatant to a new tube after each 
centrifugation. 
• Transfer the samples to 1 mL ultracentrifuge tubes and ultracentrifuge the membranes at 55,000× 
g for 15 min at 4 °C. Resuspend the pellets in 700 µL Milli-Q ultrapure water with a pipette and 
repeat the last centrifugation. 
• Resuspend the pellets in 700 µL Milli-Q ultrapure water and ultracentrifuge the membranes at 
60,000× g for 15 min at 4 °C. Resuspend the pellets in 700 µL Milli-Q ultrapure water with a 
pipette and repeat the last centrifugation. 
• Resuspend the pellets in 25 µL Milli-Q ultrapure water with a pipette. 
• Measure the concentration of bacteriorhodopsin in each sample by UV-Vis spectrometry (see 5.2 
Equipment Setup). 
3.12. Evaluation of BR Expression by Coomassie Brilliant Blue-Stained SDS-PAGE and Western blot 
analysis (0.5 Day) 
• Load membranes of each sample corresponding to 5 µg of bacteriorhodopsin on a 13.5% SDS-
PAGE gel. As a negative control, include an equivalent of H. salinarum S9 membranes 
I I ry to pick colonies of different sizes and colour intensities. Col nies with a
strong red col ur may express considerable amounts of BR-wt. In our specific case, t e c l rs
i t ar si ifica tly a t e size f t e cl es i t c rrelate ith the ratio of - - is10
t - t.
Methods Protoc. 2020, 3, x FOR PEER REVIEW 10 of 21 
 
 CRITICAL STEP Try to pick coloni s of different izes and colour intensities. Colonies with 
a strong red colour may express considerable amounts of BR-wt. In our specific case, the colours 
did not vary significantly and the size of the clones did not correlate with the ratio of BR-C-His10 
to BR-wt. 
 
Figure 2. 7-agar plate of H. salinarum L33 transform with BR-C-Hi 10. A otal of 50 µL of H. 
salinarum L33 cells transformed with BR-C-His10 was plated out after 2 days of outgrowth i  a dilution 
of 1:100 and incubated at 37 °C for two weeks. Shown is an excerpt of the plate 4 × 4 cm in size. 
3.10. Glycerol Stock Preparation (30 Min) 
• Centrifuge 8 mL of each culture at 4000× g for 15 min at room temperature and resuspend in 3.2 
mL L37. Add 800 µL of 50% (w/v) glycerol solution to reach a final concentration of 10%. Freeze 
with liquid nitrogen and store at −80 °C. 
3.11. Clone Screening by Small-Volume Purple Membrane Preparation (0.5 Day) 
• Centrifuge 10 mL of each culture at 5000× g or 15 min at 4 °C, resuspend in 1.6 mL basal salt 
and t ansf r the sample to a 2 mL Eppendorf tube. Centrifuge at 8000× g for 5 min at 4 °C and 
discard the supernatant. 
• Add 700 µL of 10 mM MgSO4 supplemented with 30 µg DNAse (=12 µL f a 2.5 mg/mL solution). 
Lyse the cells by resuspending with a pip tte until the s lution is h mogeneous. 
 CRITICAL STEP Remaining DNA leads to a viscous, inhomogeneous purple membrane 
sample and reduc s the ield. 
• R move the cell debris by centrifuging the sample  at 4300× g for 1 min at 4 °C, followed by two 
i i s at 7000× g for 1 min at 4 °C. Transfer the supernatant to a new tube after each 
centri ugation. 
• Transfer the samples to 1 mL ultracentrifuge tubes and u tracen ifuge the membranes at 55,000× 
g for 15 min a 4 °C. Resuspend the pellets in 700 µL Milli-Q ultrapure water with a pipette and 
repeat the last centrifugation. 
• Resuspend the pellets in 700 µL Milli-Q ultrapure water and ultracentrifuge the memb anes at 
60,000× g fo  15 min at 4 °C. Res spend the pellets in 700 µL Milli-Q ultrapure water with a 
pipette a  repeat the last centrifugation. 
Resuspend the pelle s in 25 µL Milli-Q ultra ure water with a pipette. 
• Measure the concentration of bacteriorhodopsin in each sample by UV-Vis spectrometry (see 5.2 
Equipment Setup). 
3.12. Evaluation of BR Expression by Coomassie Brilliant Blue-Stained SDS-PAGE and Western blot 
analysis (0.5 Day) 
• Load membranes of each sample corresponding to 5 µg of bacteriorhodopsin on a 13.5% SDS-
PAGE gel. As a negative control, include an equivalent of H. salinarum S9 membranes 
Figure 2. L37-agar plate of H. salinarum L33 transformed with BR-C-His10. A total of 50 µL of
H. salinarum L33 cells transformed ith BR-C-His10 was plated out after 2 days of outgrowth in a
dilution of 1:100 and incubated at 37 ◦C for two weeks. Shown is an excerpt of the plate 4 × 4 cm in size.
3.10. Glycerol Stock Preparation (30 in)
• Centrifuge 8 L of each culture at 4000× g for 15 min at room temperature and resuspend in
3.2 mL L37. Add 800 µL of 50% (w/v) glycerol solution to reach a final concentration of 10%.
Freeze with liquid nitrogen and store at −80 ◦C.
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3.11. Clone Screening by Small-Volume Purple Membrane Preparation (0.5 Day)
• Centrifuge 10 mL of each culture at 5000× g for 15 min at 4 ◦C, resuspend in 1.6 mL basal salt and
transfer the sample to a 2 mL Eppendorf tube. Centrifuge at 8000× g for 5 min at 4 ◦C and discard
the supernatant.
• Add 700 µL of 10 mM MgSO4 supplemented with 30 µg DNAse (=12 µL of a 2.5 mg/mL solution).
Lyse the cells by resuspending with a pipette until the solution is homogeneous.
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two centrifugations at 7000× g for 1 min at 4 ◦C. Transfer the supernatant to a new tube after
each centrifugation.
• Transfer the samples to 1 mL ultracentrifuge tubes and ultracentrifuge the membranes at 55,000× g
for 15 min at 4 ◦C. Resuspend the pellets in 700 µL Milli-Q ultrapure water with a pipette and
repeat the last centrifugation.
• Resuspend the pellets in 700 µL Milli-Q ultrapure water and ultracentrifuge the membranes at
60,000× g for 15 min at 4 ◦C. Resuspend the pellets in 700 µL Milli-Q ultrapure water with a
pipette and repeat the last centrifugation.
• Resuspend the pellets in 25 µL Milli-Q ultrapure water with a pipette.
• Measure the concentration of bacteriorhodopsin in each sample by UV-Vis spectrometry
(see Section 5.2).
3.12. Evaluation of BR Expression by Coomassie Brilliant Blue-Stained SDS-PAGE and Western blot analysis
(0.5 Day)
a membranes of each sample corresponding to 5 µg of bacteriorhodopsin on a 13.5% SDS-PAGE
gel. As a negative control, include an equivalent of H. salinarum S9 membranes corresponding
to 5 µg of bacteriorhodopsin (for expression and purification of S9 membranes see Sections 3.14
and 3.15 of this protocol). If available, as a positive control, include an equivalent of membranes
from a H. salinarum strain, expressing a His10-tagged bacteriorhodopsin corresponding to 5 µg of
bacteriorhodopsin. Run the electrophoresis at 200 V until the dye front reaches the end of the gel
and stain the gel using Coomassie Brilliant blue R-250 according to standard protocols.
• For Western blot, load an equivalent of membranes of each sample corresponding to 0.5 µg of
bacteriorhodopsin on a 13.5% SDS-PAGE gel. As a negative control, include an equivalent of
H. salinarum S9 membranes corresponding to 0.5 µg of bacteriorhodopsin. Run the electrophoresis
at 200 V.
• Transfer the samples onto a PVDF-membrane, e.g., using a semi-dry blotting system. Incubate
the membrane in 30 mL TBS containing 3% (w/v) BSA for 1 h at room temperature under gentle
agitation to reduce unspecific binding of the antibodies.
• Incubate the membrane with anti-penta-His mouse primary antibody diluted 1:3000 in 30 mL TBS
containing 3% (w/v) BSA for 1 h at room temperature under gentle agitation.
• Wash the membrane three times with 30 mL TBS containing 0.5% (v/v) Tween 20 for 10 min at
room temperature under gentle agitation. Incubate with goat anti-mouse horseradish peroxidase
(HRP)-conjugated secondary antibody diluted 1:3000 in 30 mL TBS containing 3% (w/v) BSA for 1
h at room temperature under gentle agitation.
• Wash the membrane three times with 30 mL TBS containing 0.5% (v/v) Tween 20 for 10 min at
room temperature under gentle agitation.
• Add 2 mL of ECL-detection reagent (1 mL of each) to the membrane and incubate for 2 min at
room temperature under gentle agitation. Seal the membrane in a plastic bag and expose an
X-ray film.
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• Estimate the ratio of His10-tagged to wild-type bacteriorhodopsin in the different samples by
SDS-PAGE (Figure 3a) and identify the best clone(s). If a pure clone could be obtained (i.e., no or
a very small lower band), continue working with the glycerol stock of the corresponding clone.
As an example, in Figure 3a, clone number 2 (C2) contains a considerable amount of BR-wt, while
clone number 4 (C4) can be considered of high purity. The Western blot in Figure 3b shows that
clone C4 contains the engineered C-terminal His10-tag. A smaller band around 50 kDa indicates
the presence of SDS-resistant BR-C-His10 dimers.
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membranes corresponding to 5 µg of bacteriorhodopsin were loaded. (b) Western blot analysis of BR-
wt and BR-C-His10 (C4) performed using an SDS gel run under similar conditions as in (a). The 
primary and secondary antibodies used were mouse monoclonal anti-penta-His antibody (dilution 
1:3000) and horseradish peroxidase-conjugated goat anti-mouse antibody (dilution 1:3000), 
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BR-wt showed no band, due to the absenc of a His10-tag. BR-C-His10 reacted with the nti-pen a-His
antibody, confirming the presence of the introduced His10-tag. A weaker band around 50 kDa indicates
the presence of SDS-resistant BR-C-His10 dimers.
3.13. Iterative Clone-Picking to Optimize Expression of Engineered BR (2–3 Weeks)
• If the ratio of His10-tagged to wild-type bacteriorhodopsin of the best clone is not satisfactory,
inoculate 20 mL of L37 supplemented with 0.3 µg/mL novobiocin in a 50 mL conical vial with 10 µL
of the glycerol stock of the best clone and incubate at 170 rpm for 1 week at 40 ◦C. Prepare from this
culture new L37-agar plates, pick clones and repeat the analysis as described in Sections 3.8–3.12.
This process may have to be iterated several times to obtain a clone that only expresses the
His10-tagged bacteriorhodopsin construct.
3.14. Large-Volume Cultivation of a Selected Transformed H. Salinarum L33 Clone (2 Weeks)
• Inoculate 50 mL of L37 supplemented with 0.3 µg/mL novobiocin in a 250 mL Erlenmeyer flask
with 50 µL of the glycerol stock of the selected clone. Incubate at 170 rpm for 1 week at 40 ◦C.
• Inoculate 2 L of L37 supplemented with 0.3 µg/mL novobiocin in a 5 L Erlenmeyer flask with 40
mL of the previous culture. Incubate at 170 rpm for 1 week at 40 ◦C. For a standard large-volume
cultivation, we inoculate three flasks containing 2 L of each medium.
Methods Protoc. 2020, 3, 51 13 of 22
3.15. Purple Membrane Preparation (1.5 Days)
• Centrifuge the culture at 10,000× g for 20 min at 4 ◦C, resuspend the pellet in 400 mL basal salt
using a 25 mL serological pipette and repeat the last centrifugation. Before centrifugation, measure
the weight of the empty centrifugation tubes to determine the cell mass.
• Resuspend the pellet in 25 mL/g cell mass of Milli-Q ultrapurified water supplemented with 0.02%
(w/v) NaN3 (preservative to inhibit bacterial growth). Add 1 mg DNase/g cell mass and gently stir
the solution at 4 ◦C overnight to lyse the cells by osmotic shock.
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I I Remaining DNA leads to a viscous, inhomogeneous purple membrane
sample and reduces the yield.
• Remove the cell debris by centrifuging the sample at 4300× g for 10 min at 4 ◦C, followed by two
centrifugations at 7600× g for 10 min at 4 ◦C. Transfer the supernatant to a new tube after each
centrifugation. Over the course of the three centrifugations, the cell debris pellets should change
in color from brown to purple.
• Transfer the supernatant to two 94 mL ultracentrifuge tubes, fill them up with Milli-Q ultrapurified
water and ultracentrifuge at 55,000× g for 1 h at 4 ◦C. Resuspend the pellets in Milli-Q ultrapurified
water with a pipette, combine them in one 94 mL ultracentrifuge tube, fill it up with Milli-Q
ultrapurified water and repeat the last centrifugation.
Methods Protoc. 2020, 3, x FOR PEER REVIEW 12 of 21 
 
anti-penta-His antibody, confirming the presence of the introduced His10-tag. A weaker band around 
50 kDa indicates the presence of SDS-resistant BR-C-His10 dimers. 
3.13. Iterative Clone-Picking to Optimize Expression of Engineered BR (2–3 Weeks) 
• If the ratio of His10-tagged to wild-type bacteriorhodopsin of the best clone is not satisfactory, 
inoculate 20 mL of L37 supplemented with 0.3 µg/mL novobiocin in a 50 mL conical vial with 
10 µL of the glycerol stock of the best clone and incubate at 170 rpm for 1 week at 40 °C. Prepare 
from this culture new L37-agar plates, pick clones and repeat the analysis as described in sections 
3.8 to 3.12. This process may have to be iterated several times to obtain a clone that only expresses 
the His10-tagged bacteriorhodopsin construct. 
3.14. Large-Volume Cultivation of a Selected Transformed H. Salinarum L33 Clone (2 Weeks) 
• Inoculate 50 mL of L37 supplemented with 0.3 µg/mL novobiocin in a 250 mL Erlenmeyer flask 
with 50 µL of the glycerol stock of the selected clone. Incubate at 170 rpm for 1 week at 40 °C. 
• Inoculate 2 L of L37 supplemented with 0.3 µg/mL novobiocin in a 5 L Erlenmeyer flask with 40 
mL of the previous culture. Incubate at 170 rpm for 1 week at 40 °C. For a standard large-volume 
cultivation, we inoculate three flasks containing 2 L of each medium. 
3.15. Purple Membrane Preparation (1.5 Days) 
• Centrifuge the culture at 10,000× g for 20 min at 4 °C, resuspend the pellet in 400 mL basal salt 
usi g a 25 mL s rological pipette and repeat the last centrifugation. Before centrifugation, 
measure the eight of the empty centrifugation tubes to determine the c ll mass. 
• Resuspend the pell t in 25 mL/g c ll mass of Milli-Q ultrapurified water supplemented with 
0.02% (w/v) NaN3 (pres rvative to inhibit bacterial growth). Add 1 mg DNase/g cell mass and 
gently stir the solution at 4 °C overnight to lyse the cells by osmotic shock. 
 CRITICAL STEP Remaining DNA leads to a viscous, inhomogeneous purple membran  
sample and reduces the yield. 
• Remove th  cell debris by centrifuging the sample at 4300× g for 10 min at 4 °C, followed by two 
centrifugations at 7600× g for 10 min at 4 °C. Transfer th  supern ta t to a new tube after each 
centrifugation. Over the course of the three centrifugations, the cell debris pellets should change 
in color from brown to purple. 
• Transfer the supernatant t  two 94 mL ultracentrifuge tubes, fill them up with Milli-Q 
ultrapurifi d water and ultracentrifuge at 55,000× g for 1 h at 4 °C. Resuspend the pellets in Milli-
Q ultrapurified water with a pipette, co bine them in one 94 mL ultracentrifuge tube, fill it up 
with Milli-Q ultrapurified water  repeat the last centrifugation. 
 CRITICAL STEP There mi ht still b  some remaining ell debris as a gray spot a  the center 
of th  pellets. R suspend the purple parts around it very carefully with a pipette by letting the 
water flow over the pellet without detaching the gray part from the wall of the tube. If the gray 
spots ar  relatively small, the whole pellets can be resuspended after the first centrifugation. It 
will be easier to separate the cell debris after the second centrifugation when the two gray spots 
from the previous pellets are combined in one spot. 
• Resuspend the pellet in Milli-Q ultrapurified water in the same tube with a pipette and 
ultracentrifuge at 60,000× g for 1 h at 4 °C. Resuspend the pellet with Milli-Q ultrapurified water 
in the same tube and repeat the last centrifugation. 
• Resuspend the pellet in ~0.5 mL/g cell mass of Milli-Q ultrapurified water supplemented with 
0.02% (w/v) NaN3 with a pipette and homogenize using a glass homogenizer. You may have to 
adjust the volume depending on the expression efficiency of your construct and the 
concentration needed for following experiments. 
• Measure the concentration of bacteriorhodopsin in your sample by UV-Vis spectrometry (see 5.2 
Equipment Setup). 
I I re ig t still e s r i i ll ris s r s t t t c t r
f t ellets. s s t r l rts r it r c r f ll it i tt l tti t
ater flo over t e ellet it t et c i t r rt fr t ll f t e e. If t r
s ts r relati el s ll, t e le pellets ca be resuspen e after the first centrifugatio . It
ill e easier t se r te t e cell e ris fter t e sec ce trif ti e t e t r s ts
fr t e revious pellets are co bined in one spot.
• Resuspend the pellet in illi- ultrapurified ater in the sa e tube ith a pipette and
ultracentrifuge at 60,000× g for 1 h at 4 ◦C. Resuspend the pellet with Milli-Q ultrapurified
water in the same tube and repeat the last centrifugation.
• Resuspend the pellet in ~0.5 mL/g cell mass of Milli-Q ultrapurified water supplemented with
0.02% (w/v) NaN3 with a pipette and homogenize using a glass homogenizer. You may have to
adjust the volume depending on the expression efficiency of your construct and the concentration
needed for following experiments.
• Measure the concentration of bacteriorhodopsin in your sample by UV-Vis spectrometry (see
Section 5.2).
• Determine the purity of your sample and validate the presence of the His10-tag by Coomassie
Brilliant blue-stained SDS-PAGE and Western blot (see Section 3.12).
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• In the meantime, add 2 mL of hydration buffer to the dried lipid and shake it for around 30 min
until the lipid is completely resuspended.
• Assemble the extruder with a 200 nm pore size membrane and one filter support on each side.
Flush it with 1 mL of hydration buffer using the syringes to pass the solution back and forth. Then,
pass the liposome suspension through in the same way 19 times. With an increasing number of
passages, the suspension should become more transparent, indicating a reduction in particle size.
• Start this step before the centrifugation of solubilized BR. Destabilize the extruded liposomes with
0.4% (w/v) OG by adding 83 µL of 10% (w/v) OG for 15 min with gentle shaking.
• Add the solubilized BR to the destabilized liposomes and incubate with gentle shaking for 30 min.
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• In the eanti e, soak the dialysis tubing and rinse it ith illi-Q ultrapure water.
• Close the dialysis tubing on one side with a plastic clip, fill in the protein liposome mixture and
then close the other side with a second plastic clip. Place the filled dialysis tube in 2 L of dialysis
buffer. Add a magnetic stir bar and dialyse overnight at 4 ◦C with gentle stirring. Up to two
samples can be dialysed together in 2 L of dialysis buffer.
• Harvest the dialysed samples and ultracentrifuge them 10 min at 200,000× g. Resuspend the pellet
in 1 mL of measuring solution by pipetting and centrifuge again. Wash the samples once more by
repeating the resuspension and centrifugation, and finally resuspend the proteoliposomes in 800
µL of measuring solution.
3.17. Functional haracterization of B Proteoliposo es by Photoactivity ssay (1 ay)
• Transfer the proteoliposome suspension to a clear unautoclaved 2 mL tube and add an appropriately
sized magnetic stir bar. Autoclaved tubes tend to get cloudy, thus reducing the illumination of the
samples in the next step.
• The photoactivity of the proteoliposomes is assessed by measuring the pH change in the
extravesicular medium upon illumination using a micro pH electrode. The sample should
be constantly stirred and cooled to 18 ◦C by placing the tube in a transparent glass cooling cell
with a water jacket. Illumination is provided by a warm white LED lamp (i.e., full spectrum).
Data are collected in intervals of 30 s using a computer connected to the pH meter and running an
appropriate pH meter software. Optimal illumination cycles for the described proteoliposomes
comprise an initial 15 min adaptation period in the dark, followed by alternating periods of
illumination and darkness of 15 min each (see Figure 4). Make sure to collect at least 4 peaks as
the first one might exhibit unfavourable fluctuations. For a detailed overview and an illustration
of the setup, see Hirschi et. al. (2019) [67].
• Finally, the data can be corrected for continuous pH drift by making the following approximation.
A continuous piecewise linear function is constructed from the starting points of each illumination
cycle and subtracted from the pH curve. This will set the starting points of each cycle to 0, thus
converting the scale to relative pH change and removing any drift occurring during the recording.
For a more detailed description of this process consult Harder et. al. (2016) [68].
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measurements of measuring solution (Background) or BR-wt, BR-C-His10 and BR-D98N-C-His10 
proteoliposomes. Yellow and gray shading indicate 15 min light and dark cycles. The pH of the 
extracellular solution of proteoliposomes containing functional BR versions (wt and C-His10) increases 
upon illumination, demonstrating the proton pumping activity and thus functional insertion. In 
contrast BR-D96N-C-His10 proteoliposomes exhibit only background level pH change upon 
illumination since D96N is a BR version with defective proton pumping activity. All proteoliposomes 
were reconstituted with the same amount of protein; thus, the increased pH change of the His-tagged 
version is either due to higher protein activity or more efficient reconstitution. 
3.18. Structural Characterization of Purple Membranes by Negative Stain Transmission Electron 
Microscopy (1 Day) 
• Prepare 0.75% (w/v) uranyl formate solution and filter it with a 0.2 µm syringe filter before use 
to remove any precipitates. 
• Carbon-coated copper grids are placed with the coated (shiny) side facing up on a Parafilm-
wrapped microscope slide. Use precision forceps while handling microscope grids and only 
hold them on the edges to avoid damaging the center. Grids are then glow discharged for 10 s 
under vacuum. 
 CRITICAL STEP Glow discharging electron microscopy grids is essential for the efficient 
adsorption of hydrophilic samples such as proteoliposomes to the hydrophobic grids. However, 
excessive glow discharging should be avoided as it can damage the extremely thin carbon layer. 
• A total of 5 µL of purple membrane at a concentration of about 1 mg/mL is adsorbed onto a glow 
discharged grid for 1 min. 
• The liquid is removed by gently touching the side of the grid with blotting paper. Then, the grid 
is immediately washed three times by placing a 5 µL drop of ultrapure water on the grid and 
removing it using the blotting paper. 
• A total of 5 µL of uranyl formate solution is placed on the grid and immediately blotted. Then, 
another drop is added and incubated for 10 s before drying the grid again with blotting paper. 
Finally, let the grids air dry for a few minutes before placing them in a grid storage box. 
i r . t cti ity f i tit t i t li s . ift- t t ti it
ts i l i ( or BR- t, BR-C-His10 a BR- 98 - - is10
s. Ye low and gray s a ing i icate i . he f
i ti l i s t 10) i cr
il u ination, demonstrating the proton pumping activity and thus functional insertion. In contrast
BR-D96N-C-His10 proteoliposom s exhibit only background level pH change upon illumination since
D96N is a BR version with defective proton pumping activity. All proteoliposomes we e reconstitut d
ith the same amount of protein; thus, the increased pH change of the His-tagged version is either due
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3.18. Structural Characterization of Purple Membranes by Negative Stain Transmission Electron Microscopy
(1 Day)
• Prepare 0.75% (w/v) uranyl formate solution and filter it with a 0.2 µm syringe filter before use to
remove any precipitates.
• Carbon-coated copper grids are placed with the coated (shiny) side facing up on a
Parafilm-wrapped microscope slide. Use precision forceps while handling microscope grids and
only hold them on the edges to avoid damaging the center. Grids are then glow discharged for 10
s under vacuum.
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• A total of 5 µL of purple e brane at a concentration of about 1 g/ L is adsorbed onto a glow
discharged grid for 1 in.
• The liquid is removed by gently touching the side of the grid with blotting paper. Then, the grid
is immediately washed three times by placing a 5 µL drop of ultrapure water on the grid and
removing it using the blotting paper.
• A total of 5 µL of uranyl formate solution is placed on the grid and immediately blotted. Then,
another drop is added and incubated for 10 s before drying the grid again with blotting paper.
Finally, let the grids air dry for a few minutes before placing them in a grid storage box.
• The general procedure of operating a transmission electron microscope can be obtained from the
operating manual. The size and morphology of the purple membrane patches (see Figure 5) can
be assessed at low magnification (e.g., 5–10,000×). The structural integrity and organization of
the BR crystals can be assessed by imaging the patches at higher magnification (e.g., 68,000×)
and observing the power spectrum via the Fourier transformation of corresponding images (see
Figure 5 insets).
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Figure 5. Structural characterization of purple e branes by negative stain transmission electron
microscopy. Electron micrographs of negatively stained purple membrane patches containing BR-wt
(a), BR-C-His10 (b) and BR-D96N-C-His10 (c). Insets show the power spectra of selected areas at higher
magnification and demonstrate the crystallinity of the membrane patches. Scale bars represent 500 Å
and 50 Å−1 in the insets.
4. Expected Results
We have presented a detailed protocol on the production of an engineered BR version having
a C-termi His10-tag (BR-C-H 10). Furthermore, we have described the isolatio procedure,
and functional and structural analy is of the resulting PMs containing His-tagged BR. Importantly, this
protocol opens the possibility to scientists to tailor own versions of BR for specific applications in basic
research and applied sciences.
We first introduced a His10-tag at the C-terminus of the bop gene in the pUC18 vector and
subsequently cloned the bop-C-His10 gene into the pHS blue vector. H. salinarum L33 cells were then
transformed with the resulting construct, and the PMs of several clones were isolated and analysed by
SDS-PAGE (Figure 3). The BR-deficient H. salinarum L33 [53,54] strain has the tendency to produce
revertants via homologous recombination between the transformed bop gene copy and the native
bop gene [46,69], which is here partially disrupted by an insertion element [54]. This might result in
purpl membranes containing mixtures of BR-wt and the desired engine red version, e.g., BR-C-His10
(Figure 3). To avoid this, rounds of c one optimization as desc ibed in the protoc are necessary and
were applied to obtain a c one producing m ximal amounts of His-tagged BR (Figure 3). After the
successful identification of a suitable clone, larger cultures were grown and the isolated PMs were
biochemically, functionally and structurally analysed.
BR-C-His10 and BR-wt as control were reconstituted using DOPC lipids and their functions
studied using a photoactivity assay. Upon illumination, BRs incorporated in the proteoliposomes pump
protons into the lumen, which can be detected in the surrounding medium using a micro pH-electrode
(Figure 4). Proteoliposomes containing BR-C-His10 or BR-wt produced a pH-gradient of comparable
amplitude upon illumination, which decays when the illumination is stopped. This shows that the
C-terminal His10-tag is not interfering with the proton pumping function of BR. Transmission electron
microscopy analysis of PMs containing BR-C-His10 (Figure 5b) shows comparable sizes and shapes of
membrane patches a for PMs containing BR-wt (Figur 5a). Power spectra calculated from electron
micr gr phs indicated that His-tagg d PM patches possess the same highly ordered hexagonal 2D
crystal structure (Figure 5b, inset) as PMs containing BR-wt (Figure 5a, inset). This demonstrates
that the introduction of a C-terminal His10-tag is not interfering with the formation of the typical
PM structure.
Building on BR-C-His10, a functional mutant of BR that has a significantly prolonged M-state, i.e.,
~1000-fold longer than that of BR-wt, was created by introducing a point mutation into the His-tagged
construct (BR-D96N-C-His10) [37,70]. For such mutants, it is important to introduce the mutation
into a BR version, which has a different molecular mass than the wild-type form, e.g., BR-C-His10, in
order to be able to differentiate between mutant version and revertant wild-type BR by SDS-PAGE.
The point mutation leading to a version of BR in which the aspartate at position 96 is exchanged for an
Methods Protoc. 2020, 3, 51 17 of 22
asparagine, was introduced into the bop-C-His10 gene in the pUC18 vector followed by cloning into
the pHS blue vector. Next, H. salinarum L33 was transformed with the resulting construct (pHS blue
BR-D96N-C-His10) and the PMs of several clones were isolated. Already after the first round of testing,
a clone only expressing BR-D96N-C-His10, and no BR-wt, could be obtained. PMs of a larger culture of
the selected clone were isolated, and the purity and integrity assessed by SDS-PAGE (Figure 6a) and
Western blot analysis (Figure 6b). The former showed only one band at the expected size and no BR-wt
band, while the later technique confirmed the presence of the introduced His-tag. A less prominent
band around 50 kDa, indicated the presence of a minor fraction of SDS-resistant BR-D96N-C-His10
dimers [38,39]. This purple membrane preparation yielded 2.5 mg of BR-D96N-C-His10 (for BR
quantifications refer to Section 5.2) per liter of cell culture. While yields can differ significantly between
different constructs, yields of ~5 mg per liter of cell culture for wild-type BR from H. salinarum S9 and
~1–3 mg per liter of cell culture for mutants expressed in H. salinarum L33 can be expected.
Methods Protoc. 2020, 3, x FOR PEER REVIEW 16 of 21 
 
Building on BR-C-His10, a functional mutant of BR that has a significantly prolonged M-state, 
i.e., ~1000-fold longer than that of BR-wt, was created by introducing a point mutation into the His-
tagged construct (BR-D96N-C-His10) [37,70]. For such mutants, it is important to introduce the 
mutation into a BR version, which has a different molecular mass than the wild-type form, e.g., BR-
C-His10, in order to be able to differentiate between mutant version and revertant wild-type BR by 
SDS-PAGE. The point mutation leading to a version of BR in which the aspartate at position 96 is 
exchanged for an asparagine, was introduced into the bop-C-His10 gene in the pUC18 vector followed 
by cloning into the pHS blue vector. Next, H. salinarum L33 was transformed with the resulting 
construct (pHS blue BR-D96N-C-His10) and the PMs of several clones were isolated. Already after the 
first round of testing, a clone only expressing BR-D96N-C-His10, and no BR-wt, could be obtained. 
PMs of a larger culture of the selected clone were isolated, and the purity and integrity assessed by 
SDS-PAGE (Figure 6a) and Western blot analysis (Figure 6b). The former showed only one band at 
the expected size and no BR-wt band, while the later technique confirmed the presence of the 
introduced His-tag. A less prominent band around 50 kDa, indicated the presence of a minor fraction 
of SDS-resistant BR-D96N-C-His10 dimers [38,39]. This purple membrane preparation yielded 2.5 mg 
of BR-D96N-C-His10 (for BR quantifications refer to 5.2 Equipment Setup) per liter of cell culture. 
While yields can differ significantly between different constructs, yields of ~5 mg per liter of cell 
culture for wild-type BR from H. salinarum S9 and ~1–3 mg per liter of cell culture for mutants 
expressed in H. salinarum L33 can be expected. 
 
Figure 6. Analysis of BR-D96N-C-His10 by SDS-PAGE and Western blotting. (a) Coomassie Brilliant 
blue-stained 13.5% SDS/polyacrylamide gel of isolated purple membranes from H. salinarum L33 
transformed with BR-D96N-C-His10 and BR-wt (isolated from H. salinarum S9) as a control. BR-D96N-
C-His10 migrates slower compared to BR-wt, because of the additional His10-tag. In each lane, purple 
membranes corresponding to 10 µg of bacteriorhodopsin were loaded. (b) The Western blot analysis 
of BR-wt and BR-D96N-C-His10 performed under similar conditions as in (a). The primary and 
secondary antibodies used were mouse monoclonal anti-penta-His antibody (dilution 1:3000) and 
horseradish peroxidase-conjugated goat anti-mouse antibody (dilution 1:3000), respectively. BR-wt 
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i r 6. Analysis of BR-D96N-C-His10 by SDS-PAGE and Western blotting. (a) Coomassie
Brilliant blue-stained 13.5% SDS/polyacrylamide gel of isolated purple membranes from H. salinarum
L33 transformed with BR-D96N-C-His10 and BR-wt (isolated from H. salinarum S9) as a control.
BR-D96N-C-Hi 10 mig ates slower compared to BR-wt, b c use of the additional His10-t g. In each
lane, purple membra es corresponding to 10 µg f bacteriorhodopsin were loaded. (b) The Western
blot analysis of wt and BR-D96N-C-His10 performed under similar conditions as in (a). The primary
and secondary antibodies used were mouse monoclo al anti-penta-His antibody (dilution 1:3000)
and horseradish peroxidase-conjugated goat anti-mouse antibody (dilution 1:3000), respectively.
BR- t sh wed no band, due to the absence of a His10-tag. BR-D96N-C-H s10 r acted wi h the
-penta-His antibody, confirming the pr sence of the introduced His10-tag. A weaker band around
50 kDa, indicates the presence of SDS-resistant BR-D96N-C-His10 dimers [38,39].
Analogous to BR-wt and BR-C-His10, BR-D96N-C-His10 was reconstituted in DOPC lipids
and its functional properties were analysed using the photoactivity assay described previously
(Figure 4). In contrast to BR-C-His10, BR-D96N-C-His10 did not produce a pH change upon illumination.
This confirms the expected slowing of the proton pumping activity by the introduction of the D96N
utation. To test, if the isolated utant P s for the sa e distinct patches and have the sa e 2D
crystal structure, they were structurally analysed by negative stain trans ission electron icroscopy
(Figure 5c). The electron icrographs of the P s containing BR-D96N-C-His1 showed si ilar shapes
and sizes of patches as the ones for P s containing BR- t (Figure 5a) and BR-C- is (Figure 5b).
Analysis of calculated power spectra confirmed that the PMs retain their typical hexagonal 2D crystal
lattice (Figure 5c, inset).
The obtained results from BR versions show that the presented protocol is applicable for
the production of BR variants containing a purification tag or functional mutation. Importantly,
the engineered modifications had no effect on the 2D assembly into PMs preserving this unique and
highly valuable feature.
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5. Setup
5.1. Reagent Setup
TAE buffer: Mix 40 mM Tris base, 20 mM acetic acid and 1 mM EDTA.
LB medium: Dissolve 25 g/L LB Broth powder in deionized water and autoclave.
LB-agar plates: Dissolve 25 g/L LB Broth powder in deionized water. Add 15 g/L Bacto™ Agar
and autoclave.
L37 medium: Mix 10.2 mM trisodium citrate dihydrate, 4.3 M NaCl, 80 mM MgSO4, 27 mM KCl,
and 10 g/L bacteriological peptone in deionized water. Adjust with NaOH to pH 7 at room temperature
and sterilize for 2 h at 90 ◦C in a dry sterilizer.
Novobiocin stock solution: Dissolve 1 mg/mL novobiocin sodium salt in Milli-Q ultrapure water.
Sterilize by filtration.
L37-agar plates: Mix 10.2 mM trisodium citrate dihydrate, 4.3 M NaCl, 80 mM MgSO4, 27 mM
KCl, and 10 g/L bacteriological peptone in deionized water. Adjust with NaOH to pH 7 at room
temperature. Add 15 g/L Bacto™ Agar and sterilize for 2 h at 90 ◦C in a dry sterilizer.
Spheroplast buffer (SPH): Mix 50 mM Tris-HCl (from 1 M stock solution at pH 8.75), 2 M NaCl,
27 mM KCl, and 150 g/L sucrose in Milli-Q ultrapure water. Sterilize by filtration.
EDTA solution: Dissolve 500 mM EDTA in SPH.
PEG solution: Mix 3 parts of PEG600 with 2 parts of SPH.
Spheroplast dilution solution: Mix 10.2 mM trisodium citrate dihydrate, 50 mM Tris-HCl (from
2 M stock solution adjusted to pH 7.4), 4.3 M NaCl, 80 mM MgSO4, 27 mM KCl, 1.55 mM CaCl2,
and 150 g/L sucrose in Milli-Q ultrapure water. Sterilize by filtration.
Regeneration medium: Dissolve 150 g/L sucrose in L37 medium. Sterilize by filtration.
50% (v/v) glycerol solution: Mix glycerol and Milli-Q ultrapure water 1:1 and autoclave.
Basal salt: Mix 4.3 M NaCl, 80 mM MgSO4, and 27 mM KCl in deionized water and autoclave.
DNAse solution: Prepare a 2.5 mg/mL solution from the lyophilized DNAse using Milli-Q
ultrapure water.
Tris-buffered saline (TBS): Mix 50 mM Tris and 150 mM NaCl in Milli-Q ultrapure water and
adjust the pH to pH 8.
Hydration buffer: Mix 0.76 g/L KH2PO4, 2.51 g/L K2HPO4 and 100 mM KCl in Milli-Q ultrapure
water and confirm the pH. If it is not 7.2, adjust accordingly.
Dialysis buffer: Mix 20 mM Tris and 150 mM NaCl in cold Milli-Q ultrapure water. Adjust the pH
with HCl to 8 at 4 ◦C and fill up to 2 L with Milli-Q ultrapure water.
Measuring solution: Adjust a solution of 150 mM NaCl to pH 7.4 with NaOH and always check
the pH immediately before use. Optionally, degas the solution with nitrogen gas to increase the
pH stability.
5.2. Equipment Setup
L37-Agar plates: Due to the high sodium chloride concentration of L37-agar plates and the long
incubation time (up to several weeks), it is necessary to seal the plates airtight, to prevent evaporation
and salt crystal formation. This can be achieved by packing the plates into sealed plastic bags or by
sealing the plates with several rounds of a standard plastic adhesive tape prior to incubation.
Chromophore-based protein quantification: To quantify the concentration of bacteriorhodopsin
in a purple membrane suspension, the absorption at 568 nm is measured using a spectrophotometer.
We use the UV-Vis program of a Thermo Fisher NanoDrop 1000 with measurements at 280 nm and
568 nm. High-quality purple membranes show a A280/A568 ratio of 2 [1] and lower. A higher ratio
indicates the presence of proteins other than bacteriorhodopsin.
The concentration of bacteriorhodopsin in suspensions of purple membranes can be estimated by
using a molar extinction coefficient of 63,000 L·mol−1·cm−1 at 568 nm [6].
Methods Protoc. 2020, 3, 51 19 of 22
Supplementary Materials: The following are available online at http://www.mdpi.com/2409-9279/3/3/51/s1,
Material S1: Nucleotide sequence of pHS blue, Figure S1: Vector map of pHS blue.
Author Contributions: Conceptualization, M.S., S.H., D.H., R.S. and D.F.; methodology, M.S., S.H., Z.U., D.H., R.S.
and D.F.; formal analysis, M.S., S.H., Z.U., D.H., R.S. and D.F.; investigation, M.S., S.H., D.H. and Z.U.; resources,
Z.U., R.S. and D.F.; writing—original draft preparation, M.S., S.H. and D.F.; writing—review and editing, M.S.,
S.H., R.S. and D.F.; visualization, M.S. and S.H.; supervision, D.F.; funding acquisition, R.S. and D.F. All authors
have read and agree to the published version of the manuscript.
Funding: This work was supported by the University of Bern, the National Centre of Competence in Research
(NCCR) Molecular Systems Engineering and the Swiss National Science Foundation (SNSF), as well as by the
German Research Foundation via the SFB-1078 project B4 (to R.S.).
Acknowledgments: The authors thank Ulf Eidhoff for providing the pHS blue vector. Electron microscopy
experiments were performed on equipment supported by the Microscopy Imaging Center (MIC) of the University
of Bern, Switzerland.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. Oesterhelt, D.; Stoeckenius, W. Rhodopsin-like protein from the purple membrane of Halobacterium halobium.
Nat. New Biol. 1971, 233, 149–152. [CrossRef] [PubMed]
2. Zscherp, C.; Schlesinger, R.; Tittor, J.; Oesterhelt, D.; Heberle, J. In situ determination of transient pKa
changes of internal amino acids of bacteriorhodopsin by using time-resolved attenuated total reflection
Fourier-transform infrared spectroscopy. Proc. Natl. Acad. Sci. USA 1999, 96, 5498–5503. [CrossRef]
3. Sass, H.J.; Büldt, G.; Gessenich, R.; Hehn, D.; Neff, D.; Schlesinger, R.; Berendzen, J.; Ormos, P. Structural
alterations for proton translocation in the M state of wild-type bacteriorhodopsin. Nature 2000, 406, 649–653.
[CrossRef]
4. Lanyi, J.K. Bacteriorhodopsin. Annu. Rev. Physiol. 2004, 66, 665–688. [CrossRef] [PubMed]
5. Lorenz-Fonfria, V.A.; Saita, M.; Lazarova, T.; Schlesinger, R.; Heberle, J. pH-sensitive vibrational probe reveals
a cytoplasmic protonated cluster in bacteriorhodopsin. Proc. Natl. Acad. Sci. USA 2017, 114, E10909–E10918.
[CrossRef] [PubMed]
6. Oesterhelt, D.; Hess, B. Reversible photolysis of the purple complex in the purple membrane of
Halobacterium halobium. Eur. J. Biochem. 1973, 37, 316–326. [CrossRef]
7. Lewis, A.; Spoonhower, J.; Bogomolni, R.A.; Lozier, R.H.; Stoeckenius, W. Tunable laser resonance Raman
spectroscopy of bacteriorhodopsin. Proc. Natl. Acad. Sci. USA 1974, 71, 4462–4466. [CrossRef]
8. Lozier, R.; Bogomolni, R.; Stoeckenius, W. Bacteriorhodopsin: A light-driven proton pump in
Halobacterium halobium. Biophys. J. 1975, 15, 955–962. [CrossRef]
9. Birge, R.R. Nature of the primary photochemical events in rhodopsin and bacteriorhodopsin. Biochim. Biophys.
Acta (BBA) Bioenergy 1990, 1016, 293–327. [CrossRef]
10. Danon, A.; Stoeckenius, W. Photophosphorylation in Halobacterium halobium. Proc. Natl. Acad. Sci. USA 1974,
71, 1234–1238. [CrossRef]
11. Racker, E.; Stoeckenius, W. Reconstitution of purple membrane vesicles catalyzing light-driven proton uptake
and adenosine triphosphate formation. J. Biol. Chem. 1974, 249, 662–663. [CrossRef] [PubMed]
12. Stoeckenius, W.; Lozier, R.H. Light energy conversion in Halobacterium halobium. J. Supramol. Struct. 1974, 2,
769–774. [CrossRef] [PubMed]
13. Henderson, R.; Unwin, P.N.T. Three-dimensional model of purple membrane obtained by electron microscopy.
Nature 1975, 257, 28–32. [CrossRef] [PubMed]
14. Müller, D.J.; Schabert, F.; Büldt, G.; Engel, A. Imaging purple membranes in aqueous solutions at
sub-nanometer resolution by atomic force microscopy. Biophys. J. 1995, 68, 1681–1686. [CrossRef]
15. Pebay-Peyroula, E.; Rummel, G.; Rosenbusch, J.P.; Landau, E.M. X-ray structure of bacteriorhodopsin at 2.5
Angstroms from microcrystals grown in lipidic cubic phases. Science 1997, 277, 1676–1681. [CrossRef]
16. Kimura, Y.; Vassylyev, D.G.; Miyazawa, A.; Kidera, A.; Matsushima, M.; Mitsuoka, K.; Murata, K.; Hirai, T.;
Fujiyoshi, Y. Surface of bacteriorhodopsin revealed by high-resolution electron crystallography. Nature 1997,
389, 206–211. [CrossRef]
Methods Protoc. 2020, 3, 51 20 of 22
17. Nango, E.; Royant, A.; Kubo, M.; Nakane, T.; Wickstrand, C.; Kimura, T.; Tanaka, T.; Tono, K.; Song, C.;
Tanaka, R.; et al. A three-dimensional movie of structural changes in bacteriorhodopsin. Science 2016, 354,
1552–1557. [CrossRef]
18. Nogly, P.; Weinert, T.; James, D.; Carbajo, S.; Ozerov, D.; Furrer, A.; Gashi, D.; Borin, V.; Skopintsev, P.;
Jaeger, K.; et al. Retinal isomerization in bacteriorhodopsin captured by a femtosecond x-ray laser. Science
2018, 361, eaat0094. [CrossRef]
19. Weinert, T.; Skopintsev, P.; James, D.; Dworkowski, F.; Panepucci, E.; Kekilli, D.; Furrer, A.; Brünle, S.;
Mous, S.; Ozerov, D.; et al. Proton uptake mechanism in bacteriorhodopsin captured by serial synchrotron
crystallography. Science 2019, 365, 61–65. [CrossRef]
20. Kovacs, G.N.; Colletier, J.-P.; Grünbein, M.L.; Yang, Y.; Stensitzki, T.; Batyuk, A.; Carbajo, S.; Doak, R.B.;
Ehrenberg, D.; Foucar, L.; et al. Three-dimensional view of ultrafast dynamics in photoexcited
bacteriorhodopsin. Nat. Commun. 2019, 10, 3177. [CrossRef]
21. Sass, J.; Cordier, F.; Hoffmann, A.; Rogowski, M.; Cousin, A.; Omichinski, J.G.; Löwen, H.; Grzesiek, S. Purple
membrane induced alignment of biological macromolecules in the magnetic field. J. Am. Chem. Soc. 1999,
121, 2047–2055. [CrossRef]
22. Blaurock, A.E.; Stoeckenius, W. Structure of the purple membrane. Nat. New Biol. 1971, 233, 152–155.
[CrossRef] [PubMed]
23. Krebs, M.; A Isenbarger, T. Structural determinants of purple membrane assembly. Biochim. Biophys. Acta
(BBA) Bioenergy 2000, 1460, 15–26. [CrossRef]
24. Wagner, N.L.; Greco, J.A.; Ranaghan, M.J.; Birge, R.R. Directed evolution of bacteriorhodopsin for applications
in bioelectronics. J. R. Soc. Interface 2013, 10, 20130197. [CrossRef] [PubMed]
25. Birge, R.R.; Gillespie, N.B.; Izaguirre, E.W.; Kusnetzow, A.; Lawrence, A.F.; Singh, D.; Song, Q.W.; Schmidt, E.;
Stuart, J.A.; Seetharaman, S.; et al. Biomolecular electronics: Protein-based associative processors and
volumetric memories. J. Phys. Chem. B 1999, 103, 10746–10766. [CrossRef]
26. Chen, Z.; Govender, D.; Gross, R.; Birge, R. Advances in protein-based three-dimensional optical memories.
Biosystems 1995, 35, 145–151. [CrossRef]
27. A Stuart, J.; Marcy, D.L.; Wise, K.J.; Birge, R.R. Volumetric optical memory based on bacteriorhodopsin.
Synth. Met. 2002, 127, 3–15. [CrossRef]
28. Hampp, N.A. Bacteriorhodopsin: Mutating a biomaterial into an optoelectronic material. Appl. Microbiol.
Biotechnol. 2000, 53, 633–639. [CrossRef]
29. Ormos, P.; Fábián, L.; Oroszi, L.; Wolff, E.K.; Ramsden, J.J.; Dér, A. Protein-based integrated optical switching
and modulation. Appl. Phys. Lett. 2002, 80, 4060–4062. [CrossRef]
30. Mathesz, A.; Fábián, L.; Valkai, S.; Alexandre, D.; Marques, P.V.; Ormos, P.; Wolff, E.K.; Dér, A. High-speed
integrated optical logic based on the protein bacteriorhodopsin. Biosens. Bioelectron. 2013, 46, 48–52.
[CrossRef]
31. Walczak, K.A.; Bergstrom, P.; Friedrich, C. Light sensor platform based on the integration of bacteriorhodopsin
with a single electron transistor. Act. Passiv. Electron. Components 2011, 2011, 1–7. [CrossRef]
32. Bhattacharya, P.; Xu, J.; Váró, G.; Marcy, D.L.; Birge, R.R. Monolithically integrated bacteriorhodopsin-GaAs
field-effect transistor photoreceiver. Opt. Lett. 2002, 27, 839–841. [CrossRef] [PubMed]
33. Sharkany, J.P.; Korposh, S.O.; Batori-Tarci, Z.I.; Trikur, I.I.; Ramsden, J.J. Bacteriorhodopsin-based biochromic
films for chemical sensors. Sens. Actuators B Chem. 2005, 107, 77–81. [CrossRef]
34. Korposh, S.O.; Sharkan, Y.P.; Ramsden, J.J. Response of bacteriorhodopsin thin films to ammonia.
Sens. Actuators B Chem. 2008, 129, 473–480. [CrossRef]
35. Roy, S.; Prasad, M.; Topolancik, J.; Vollmer, F. All-optical switching with bacteriorhodopsin protein coated
microcavities and its application to low power computing circuits. J. Appl. Phys. 2010, 107, 53115. [CrossRef]
36. Greco, J.A.; Fernandes, L.A.L.; Wagner, N.L.; Azadmehr, M.; Häfliger, P.; Johannessen, E.A.; Birge, R.R.
Pixel characterization of a protein-based retinal implant using a microfabricated sensor array pixel
characterization of a protein-based retinal implant. Int. J. High Speed Electron. Syst. 2017, 26. [CrossRef]
37. Shibata, M.; Uchihashi, T.; Yamashita, H.; Kandori, H.; Ando, T. Structural changes in bacteriorhodopsin in
response to alternate illumination observed by high-speed atomic force microscopy. Angew. Chem. Int. Ed.
2011, 50, 4410–4413. [CrossRef]
Methods Protoc. 2020, 3, 51 21 of 22
38. Pfreundschuh, M.; Harder, D.; Ucurum, Z.; Fotiadis, D.; Müller, D.J. Detecting ligand-binding events and
free energy landscape while imaging membrane receptors at subnanometer resolution. Nano Lett. 2017, 17,
3261–3269. [CrossRef]
39. Laskowski, P.R.; Pfreundschuh, M.; Stauffer, M.; Ucurum, Z.; Fotiadis, D.; Müller, D.J. High-resolution
imaging and multiparametric characterization of native membranes by combining confocal microscopy and
an atomic force microscopy-based toolbox. ACS Nano 2017, 11, 8292–8301. [CrossRef]
40. Nomura, S.; Harada, Y. Functional expression of green fluorescent protein derivatives in
Halobacterium salinarum. FEMS Microbiol. Lett. 1998, 167, 287–293. [CrossRef]
41. Subramaniam, S.; Marti, T.; Khorana, H.G. Protonation state of Asp (Glu)-85 regulates the purple-to-blue
transition in bacteriorhodopsin mutants Arg-82—-Ala and Asp-85—-Glu: The blue form is inactive in proton
translocation. Proc. Natl. Acad. Sci. USA 1990, 87, 1013–1017. [CrossRef] [PubMed]
42. Patil, A.V.; Premaruban, T.; Berthoumieu, O.; Watts, A.; Davis, J.J. Enhanced photocurrent in engineered
bacteriorhodopsin monolayer. J. Phys. Chem. B 2011, 116, 683–689. [CrossRef] [PubMed]
43. Cline, S.W.; Doolittle, W.F. Efficient transfection of the archaebacterium Halobacterium halobium. J. Bacteriol.
1987, 169, 1341–1344. [CrossRef] [PubMed]
44. Cline, S.W.; Lam, W.L.; Charlebois, R.L.; Schalkwyk, L.C.; Doolittle, W.F. Transformation methods for
halophilic archaebacteria. Can. J. Microbiol. 1989, 35, 148–152. [CrossRef]
45. Lam, W.L.; Doolittle, W.F. Shuttle vectors for the archaebacterium Halobacterium volcanii. Proc. Natl. Acad.
Sci. USA 1989, 86, 5478–5482. [CrossRef]
46. Ni, B.; Chang, M.; Duschl, A.; Lanyi, J.; Needleman, R. An efficient system for the synthesis of
bacteriorhodopsin in Halobacterium halobium. Gene 1990, 90, 169–172. [CrossRef]
47. Ferrando, E.; Schweiger, U.; Oesterhelt, D. Homologous bacterio-opsin-encoding gene expression via
site-specific vector integration. Gene 1993, 125, 41–47. [CrossRef]
48. Holmes, M.L.; Dyall-Smith, M.L. A plasmid vector with a selectable marker for halophilic archaebacteria.
J. Bacteriol. 1990, 172, 756–761. [CrossRef]
49. Holmes, M.L.; Dyall-Smith, M.L. Mutations in DNA gyrase result in novobiocin resistance in halophilic
archaebacteria. J. Bacteriol. 1991, 173, 642–648. [CrossRef]
50. Krebs, M.P.; Hauss, T.; Heyn, M.P.; Rajbhandary, U.L.; Khorana, H.G. Expression of the bacterioopsin gene in
Halobacterium halobium using a multicopy plasmid. Proc. Natl. Acad. Sci. USA 1991, 88, 859–863. [CrossRef]
51. Krebs, M.P.; Mollaaghababa, R.; Khorana, H.G. Gene replacement in Halobacterium halobium and expression
of bacteriorhodopsin mutants. Proc. Natl. Acad. Sci. USA 1993, 90, 1987–1991. [CrossRef] [PubMed]
52. Holmes, M.; Pfeifer, F.; Dyall-Smith, M. Improved shuttle vectors for Haloferax volcanii including a
dual-resistance plasmid. Gene 1994, 146, 117–121. [CrossRef]
53. Wagner, G.; Oesterhelt, D.; Krippahl, G.; Lanyi, J.K. Bioenergetic role of halorhodopsin in
Halobacterium halobium cells. FEBS Lett. 1981, 131, 341–345. [CrossRef]
54. DasSarma, S.; Rajbhandary, U.L.; Khorana, H.G. High-frequency spontaneous mutation in the bacterio-opsin
gene in Halobacterium halobium is mediated by transposable elements. Proc. Natl. Acad. Sci. USA 1983, 80,
2201–2205. [CrossRef] [PubMed]
55. Karnik, S.S.; Nassal, M.; Doi, T.; Jay, E.; Sgaramella, V.; Khorana, H.G. Structure-function studies on
bacteriorhodopsin. II. Improved expression of the bacterio-opsin gene in Escherichia coli. J. Biol. Chem. 1987,
262, 9255–9263. [PubMed]
56. Nassal, M.; Mogi, T.; Karnik, S.S.; Khorana, H.G. Structure-function studies on bacteriorhodopsin. III.
Total synthesis of a gene for bacterio-opsin and its expression in Escherichia coli. J. Biol. Chem. 1987, 262,
9264–9270. [PubMed]
57. Mogi, T.; Stern, L.J.; Hackett, N.R.; Khorana, H.G. Bacteriorhodopsin mutants containing single tyrosine
to phenylalanine substitutions are all active in proton translocation. Proc. Natl. Acad. Sci. USA 1987, 84,
5595–5599. [CrossRef]
58. Shand, R.F.; Miercke, L.J.W.; Mitra, A.K.; Fong, S.K.; Stroud, R.M.; Betlach, M.C. Wild-type and mutant
bacterioopsins D85N, D96N, and R82Q: High-level expression in Escherichia coli. Biochemistry 1991, 30,
3082–3088. [CrossRef]
59. Hildebrandt, V.; Ramezani-Rad, M.; Swida, U.; Wrede, P.; Grzesiek, S.; Primke, M.; Büldt, G. Genetic transfer
of the pigment bacteriorhodopsin into the eukaryote Schizosaccharomyces pombe. FEBS Lett. 1989, 243, 137–140.
[CrossRef]
Methods Protoc. 2020, 3, 51 22 of 22
60. Hildebrandt, V.; Fendler, K.; Heberle, J.; Hoffmann, A.; Bamberg, E.; Büldt, G. Bacteriorhodopsin expressed
in Schizosaccharomyces pombe pumps protons through the plasma membrane. Proc. Natl. Acad. Sci. USA 1993,
90, 3578–3582. [CrossRef]
61. Stoeckenius, W.; Rowen, R. A morphological study of Halobacterium halobium and its lysis in media of low
salt concentration. J. Cell Biol. 1967, 34, 365–393. [CrossRef] [PubMed]
62. Stoeckenius, W.; Kunau, W.H. Further characterization of particulate fractions from lysed cell envelopes of
Halobacterium halobium and isolation of gas vacuole membranes. J. Cell Biol. 1968, 38, 337–357. [CrossRef]
[PubMed]
63. Oesterhelt, D.; Stoeckenius, W. Isolation of the cell membrane of Halobacterium halobium and its fractionation
into red and purple membrane. Methods Enzym. 1974, 31, 667–678. [CrossRef]
64. Geiser, A.H.; Sievert, M.K.; Guo, L.-W.; Grant, J.E.; Krebs, M.; Fotiadis, D.; Engel, A.; Ruoho, A.E.
Bacteriorhodopsin chimeras containing the third cytoplasmic loop of bovine rhodopsin activate transducin
for GTP/GDP exchange. Protein Sci. 2006, 15, 1679–1690. [CrossRef] [PubMed]
65. Stoeckenius, W.; Lozier, R.H.; Bogomolni, R.A. Bacteriorhodopsin and the purple membrane of halobacteria.
Biochim. Biophys. Acta (BBA) Rev. Bioenergy 1979, 505, 215–278. [CrossRef]
66. Gordeliy, V.I.; Schlesinger, R.; Efremov, R.; Büldt, G.; Heberle, J. Crystallization in lipidic cubic phases: A
case study with bacteriorhodopsin. In Membrane Protein Protocols; Humana Press Inc.: Totowa, NJ, USA,
2003; Volume 228, pp. 305–316. [CrossRef]
67. Hirschi, S.; Fischer, N.; Kalbermatter, D.; Laskowski, P.R.; Ucurum, Z.; Müller, D.J.; Fotiadis, D. Design
and assembly of a chemically switchable and fluorescently traceable light-driven proton pump system for
bionanotechnological applications. Sci. Rep. 2019, 9, 1–10. [CrossRef] [PubMed]
68. Harder, D.; Hirschi, S.; Ucurum, Z.; Goers, R.; Meier, W.P.; Müller, D.J.; Fotiadis, D. Engineering a chemical
switch into the light-driven proton pump proteorhodopsin by cysteine mutagenesis and thiol modification.
Angew. Chem. Int. Ed. 2016, 55, 8846–8849. [CrossRef]
69. Pfeiffer, M. Studies on dynamics and function of bacteriorhodopsin from Halobacterium salinarum; Herbert Utz
Verlag: Munich, Germany, 2000.
70. Otto, H.; Marti, T.; Holz, M.; Mogi, T.; Lindau, M.; Khorana, H.G.; Heyn, M.P. Aspartic acid-96 is the internal
proton donor in the reprotonation of the Schiff base of bacteriorhodopsin. Proc. Natl. Acad. Sci. USA 1989,
86, 9228–9232. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
